Utreglutide (CAS 2460862-12-6) | GMP Supplier & Manufacturer

描述

Product Description

Utreglutide (CAS 2460862-12-6) is a potent glucagon-like peptide-1 (GLP-1) receptor agonist, specifically designed to mimic the activity of endogenous incretin hormones. As a synthetic research peptide, Utreglutide plays a crucial role in advancing our understanding of metabolic pathways, glucose regulation, and potential therapeutic approaches for diabetes and obesity.

Background and Research Importance

The GLP-1 receptor is a well-characterized target in the management of type 2 diabetes mellitus and obesity. Endogenous GLP-1 enhances insulin secretion, inhibits glucagon release, slows gastric emptying, and reduces appetite. However, natural GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), limiting its therapeutic potential. Utreglutide, as a modified GLP-1 receptor agonist, is engineered for enhanced stability and prolonged biological activity, making it an invaluable research tool.

Utreglutide enables researchers to explore incretin biology, insulin sensitivity, cardiovascular function, and neuroendocrine signaling. Preclinical studies suggest that GLP-1 receptor agonists may offer benefits beyond glycemic control, including weight reduction, neuroprotection, and cardiometabolic improvements.

Chemical Properties and Structure

• Compound Type: Synthetic GLP-1 receptor agonist peptide

• Class: Incretin mimetic research peptide

• Target: GLP-1 receptor (agonist)

• Stability: Enhanced resistance to enzymatic degradation compared to native GLP-1

These properties ensure Utreglutide’s suitability for sustained biological studies across metabolic, cardiovascular, and neurological research fields.

Key Advantages in Research

• High potency at the GLP-1 receptor

• Extended stability in vitro and in vivo

• Wide applicability in metabolic and endocrinology studies

• GMP-grade synthesis ensures reproducibility and reliability

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Utreglutide acts as a full agonist of the GLP-1 receptor, activating pathways critical for glucose and energy regulation:

• Enhanced Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic β-cells.

• Inhibition of Glucagon Secretion: Suppresses inappropriate glucagon release from α-cells.

• Slowed Gastric Emptying: Delays digestion and absorption, reducing postprandial glucose spikes.

• Appetite Regulation: Influences central satiety pathways, reducing food intake.

• Cardiovascular Benefits: Enhances endothelial function, reduces blood pressure, and improves lipid metabolism in research models.

Research Applications

1. Diabetes Research
   Utreglutide provides a model for studying insulin signaling, glycemic regulation, and the therapeutic potential of GLP-1 receptor agonists in type 2 diabetes.

2. Obesity and Metabolic Disorders
   By reducing appetite and modulating energy balance, Utreglutide is used in studies exploring obesity management and weight-loss interventions.

3. Cardiovascular Studies
   GLP-1 agonists demonstrate cardioprotective effects, making Utreglutide a valuable tool for studying hypertension, atherosclerosis, and ischemic injury.

4. Neuroendocrine Research
   Recent findings indicate that GLP-1 receptor agonists may have neuroprotective roles, offering potential insights into neurodegenerative diseases.

5. Drug Interaction and Combination Studies
   Utreglutide is studied alongside DPP-4 inhibitors, SGLT2 inhibitors, and insulin analogs to assess synergistic metabolic outcomes.

   

Side Effects (For Reference in Research Models)

While Utreglutide is not intended for human or veterinary use, laboratory models have reported several outcomes:

• Gastrointestinal Effects: Nausea, vomiting, or slowed gastric motility in high-dose studies.

• Hypoglycemia: Potential when combined with other insulinotropic compounds.

• Cardiac Effects: Alterations in heart rate and blood pressure in certain animal models.

• Injection Site Reactions: Localized irritation in parenteral delivery studies.

• Long-Term Adaptations: Chronic exposure may lead to receptor desensitization in experimental models.

• Species-Specific Differences: Effects may vary depending on animal model and dosage.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

 Keywords

•  CAS 2460862-12-6

•  GLP-1 receptor agonist

• GMP-grade GLP-1 agonist peptide

• Utreglutide peptide supplier

• GLP-1 receptor agonist research

• Utreglutide diabetes research peptide

• GLP-1 obesity research agonist

• Utreglutide wholesale supplier

• Laboratory-grade GLP-1 analog

• Research use only GLP-1 agonist